RxDoctor Payments Data

Bettina Veronneau, MD

Family Medicine · Edmond, OKNPI 1083663322

Payments from drug & device makers

$11,458in general payments, 2019–2025

Across 818 payments — averaging $14.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$865
  • Boehringer Ingelheim$855
  • GSK$619
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,33499%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)136$1,690
AstraZeneca41$1,210
Novo Nordisk108$1,191
Pfizer68$865
Boehringer Ingelheim69$855
GSK58$619
Lilly USA, LLC50$592
Amgen(2 entities)37$540
Bayer32$417
Takeda Pharmaceuticals U.S.A., Inc.19$314
Amarin Pharma, Inc.25$308
Merck19$267
Abbott13$238
Sanofi-aventis U.S. LLC16$221
Astellas Pharma US Inc9$147
Johnson & Johnson9$144
Dexcom, Inc.7$109
Lundbeck LLC5$109
Eisai Inc.6$109
Supernus Pharmaceuticals, Inc.6$97
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$96
Novartis7$96
Teva Pharmaceuticals USA, Inc.5$77
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$75
Biohaven Pharmaceuticals, Inc.5$75
Kaleo, Inc.4$67
Ultragenyx Pharmaceutical Inc.4$65
Sanofi Pasteur Inc.3$48
Nabriva Therapeutics, PLC3$41
Kyowa Kirin, Inc.3$40
Genentech USA, Inc.2$38
Sunovion Pharmaceuticals Inc.2$36
Almatica Pharma LLC2$36
Sumitomo Pharma America, Inc.2$34
Shire North American Group Inc2$34
Exact Sciences2$33
E.r. Squibb & Sons, L.L.C.2$33
Shield Therapeutics Inc1$33
Otsuka America Pharmaceutical, Inc.2$31
Vanda Pharmaceuticals Inc.1$28
Dynavax Technologies Corporation2$28
Madrigal Pharmaceuticals1$27
Hologic Sales And Service, LLC1$25
Scynexis, Inc.1$24
Mayne Pharma Commercial LLC1$23
Xeris Pharmaceuticals, Inc.1$21
Edwards Lifesciences1$21
Corcept Therapeutics1$20
Cranial Technologies, Inc1$20
Biohaven Pharmaceutical Holding Company Ltd.1$20
Cequr Corporation1$17
Neos Therapeutics, LP1$16
Alnylam Pharmaceuticals Inc.1$16
Nestle Healthcare Nutrition Inc.1$15
Scilex Pharmaceuticals Inc.1$15
Paratek Pharmaceuticals, Inc.1$14
Idorsia Pharmaceuticals US Inc1$14
Esperion Therapeutics, Inc.1$13
IBSA Pharma Inc.1$13
Ironwood Pharmaceuticals, Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,458 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$128,470
Medicare patients
368
Services billed
1,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$157,722
OzempicSemaglutide72$140,753
EliquisApixaban64$64,149
MounjaroTirzepatide41$59,605
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$40,523
MyrbetriqMirabegron35$35,246
TrulicityDulaglutide22$28,507
JanuviaSitagliptin Phosphate11$18,350
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$15,464
Breo ElliptaFluticasone/Vilanterol21$15,339
Janumet XrSitagliptin Phos/Metformin Hcl11$14,644
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$11,405
Atorvastatin Calcium636$8,175
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,374
Levothyroxine Sodium463$5,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$855$157,722118 claims
Novo NordiskOzempic$1,191$140,75372 claims
Lilly USA, LLCMounjaro, Trulicity$592$88,11263 claims
PfizerEliquis$865$64,14964 claims
GSKTrelegy Ellipta, Breo Ellipta$619$55,86252 claims
Astellas Pharma US IncMyrbetriq$147$35,24635 claims
MerckJanuvia, Janumet Xr$267$32,99522 claims
AstraZenecaBreztri Aerosphere$1,210$15,46415 claims
AbbVieSynthroid$1,690$2,20533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →